Legato Capital Management’s TG Therapeutics TGTX Stock Holding History

Legato Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$480K	Buy	+14,437	New	+$430K	0.04%	543
2025 Q3	–	Sell	-19,529	Closed	-$703K	–	624
2025 Q2	$703K	Buy	19,529 +5,407	+38%	+$201K	0.08%	371
2025 Q1	$557K	Buy	14,122 +3,775	+36%	+$127K	0.08%	406
2024 Q4	$311K	Sell	10,347 -3,104	-23%	-$89.1K	0.04%	492
2024 Q3	$315K	Buy	+13,451	New	+$294K	0.04%	506
2023 Q3	–	Sell	-10,710	Closed	-$266K	–	642
2023 Q2	$266K	Buy	+10,710	New	+$277K	0.04%	491
2021 Q3	–	Sell	-19,348	Closed	-$751K	–	308
2021 Q2	$751K	Buy	+19,348	New	+$760K	0.11%	199

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Legato Capital Management's TGTX Position: Q1 2026 in Review

Legato Capital Management opened a new position in TG Therapeutics (TGTX) in Q1 2026: 14,437 shares worth $480K. The stake represents 0.04% of the portfolio and ranks #543 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in TGTX as recently as Q2 2025.

Legato Capital Management first reported a position in TGTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $751K in Q2 2021. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Legato Capital Management held 14,437 shares of TG Therapeutics worth $480K as of Q1 2026.
TG Therapeutics was a new Legato Capital Management position in Q1 2026.
TG Therapeutics made up 0.04% of Legato Capital Management's portfolio in Q1 2026, its #543 holding.
Legato Capital Management first reported a position in TG Therapeutics in Q2 2021 and has held it in 7 quarters since.
Legato Capital Management's TG Therapeutics position peaked at $751K in Q2 2021.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.